ReviewDeutsches Arzteblatt international2019
Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.
Review in Deutsches Arzteblatt international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Neoadjuvant therapy in skin cancer: current evidence and future perspectives.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Detection of vasculogenic mimicry in equine ocular, oronasal, and genital squamous cell carcinoma.PloS one · 2026Article
- A descriptive review of common dermatological diseases encountered by manual therapy providers.The Journal of the Canadian Chiropractic Association · 2025Article
- Investigation of the Causal Association Between Treg Cells and Actinic Keratosis Through Two-Sample Mendelian Randomization Analysis.Clinical, cosmetic and investigational dermatology · 2025Article
- Cost-Effectiveness Analysis of Topical Treatments for Actinic Keratosis in Italian National Health System.Journal of clinical medicine · 2024Article
- Review
- Actinic keratosis metrics.Archives of dermatological research · 2024Review
- Cutaneous Squamous Cell Carcinoma of the Head and Neck: Pathological Features and What They Mean for Prognosis and Treatment.Cancers · 2024Review
- Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.Biomedicines · 2024Review
- Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization.Archives of dermatological research · 2024Article
- An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs.Current drug delivery · 2024Review
- Field cancerization in dermatology.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Promise of Semantic Segmentation in Detecting Actinic Keratosis Using Clinical Photography in the Wild.Cancers · 2023Article
- Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States.Cancers · 2023Review
- TargetingFrontiers in oncology · 2023Article
- [Potassium hydroxide 5 % solution in actinic keratosis : A novel therapeutic approach in the lesion-directed treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Article
- Review
- A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis.Current oncology (Toronto, Ont.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous squamous cell carcinoma (cSCC) and its precursors, actinic keratoses (AK), are common. Physicians of multiple specialties are confronted with their treatment.
methodsThis review is based on publications retrieved by a selective search in PubMed, as well as on the German guidelines on AK and cSCC, skin cancer prevention, and surgery with histologic guidance.
resultsLocal treatments for AK include lesional cryotherapy, curettage, and laser ablation as well as field-directed treatments with topical agents, e.g., diclofenac plus hyaluronic acid, imiquimod, 5-fluorouracil, ingenol mebutate, and photodynamic therapy. These treatments can be administered in various sequences or combinations, depending on individual factors and the stage of the disease. The gold standard of treatment for cSCC is histologically confirmed complete resection; radiotherapy is an alternative. Locally uncontrollable or metastatic disease is treated with systemic drugs. The use of various chemotherapeutic agents, EGFR-directed therapies, and the PD-I inhibitor cemiplimab, either singly or in combination, has been described in uncontrolled trials and case series. Cemiplimab has a reported response rate of 47% and was recently approved for the treatment of advanced cSCC.
conclusionThere are many options for the treatment of AK and cSCC that must be considered in the interdisciplinary care of these entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.